Literature DB >> 21820158

Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events.

Anetta Undas1, Agnieszka Slowik, Matthew Gissel, Kenneth G Mann, Saulius Butenas.   

Abstract

BACKGROUND: Elevated factor (F)XI is associated with an increased risk for ischemic stroke. Activated FXI (FXIa) and tissue factor (TF) have not been studied following stroke. The aim of the current study was to evaluate circulating FXIa and TF in patients with prior cerebrovascular events. PATIENTS/
METHODS: We studied 241 patients, including 162 after ischemic stroke and 79 after transient ischemic attack (TIA), recruited 6 months to 4 years (median, 36 months) after the events. Plasma TF and FXIa activity following the index event were determined in clotting assays by measuring the response to inhibitory monoclonal antibodies.
RESULTS: Active TF was detected in 25 (10.4%) of the patients, while FXIa activity (median, 37.5 [IQR 397] pM) was found in 64 (26.7%) of the patients (p<0.01). The prevalence of active TF and FXIa was higher in subjects with previous stroke compared with those with a history of TIA (13% vs 5.1%, p=0.05, and 34% vs 11.4%, p<0.0001, respectively). Patients with circulating FXIa were younger and had higher fibrinogen and interleukin-6 compared to the remainder. Patients with detectable TF or FXIa activity had higher NIHSS score, higher modified Rankin scale and lower Barthel Index than the remaining subjects (all p<0.05).
CONCLUSION: Circulating active TF and FXIa can occur in patients with cerebrovascular ischemic events ≥6 months after the events. The presence of these factors is associated with worse functional outcomes, which highlights the role of persistent hypercoagulable state in cerebrovascular disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820158      PMCID: PMC3205247          DOI: 10.1016/j.thromres.2011.06.010

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  31 in total

Review 1.  Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers.

Authors:  Jan Simak; Monique P Gelderman
Journal:  Transfus Med Rev       Date:  2006-01

2.  Measurements of acute cerebral infarction: a clinical examination scale.

Authors:  T Brott; H P Adams; C P Olinger; J R Marler; W G Barsan; J Biller; J Spilker; R Holleran; R Eberle; V Hertzberg
Journal:  Stroke       Date:  1989-07       Impact factor: 7.914

3.  Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.

Authors:  David T Yang; Michele M Flanders; Hyunhee Kim; George M Rodgers
Journal:  Am J Clin Pathol       Date:  2006-09       Impact factor: 2.493

4.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.

Authors:  J H Morrissey; B G Macik; P F Neuenschwander; P C Comp
Journal:  Blood       Date:  1993-02-01       Impact factor: 22.113

5.  Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome.

Authors:  W M Feinberg; L P Erickson; D Bruck; J Kittelson
Journal:  Stroke       Date:  1996-08       Impact factor: 7.914

6.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

Authors:  P A Von dem Borne; L Bajzar; J C Meijers; M E Nesheim; B N Bouma
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

7.  Tissue factor activity in whole blood.

Authors:  Saulius Butenas; Beth A Bouchard; Kathleen E Brummel-Ziedins; Behnaz Parhami-Seren; Kenneth G Mann
Journal:  Blood       Date:  2004-12-16       Impact factor: 22.113

Review 8.  Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications.

Authors:  Jan Steffel; Thomas F Lüscher; Felix C Tanner
Journal:  Circulation       Date:  2006-02-07       Impact factor: 29.690

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis.

Authors:  Christoph Kleinschnitz; Guido Stoll; Martin Bendszus; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; Christoph Renné; David Gailani; Bernhard Nieswandt; Thomas Renné
Journal:  J Exp Med       Date:  2006-03-13       Impact factor: 14.307

View more
  13 in total

1.  Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice.

Authors:  Philberta Y Leung; Sawan Hurst; Michelle A Berny-Lang; Norah G Verbout; David Gailani; Erik I Tucker; Ruikang K Wang; Owen J T McCarty; András Gruber
Journal:  Transl Stroke Res       Date:  2012-09       Impact factor: 6.829

Review 2.  TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy.

Authors:  K G Mann; K Freeman
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

3.  Analysis of factor XIa, factor IXa and tissue factor activity in burn patients.

Authors:  Jeffrey W Shupp; Shannon M Prior; Daniel Y Jo; Lauren T Moffatt; Kenneth G Mann; Saulius Butenas
Journal:  Burns       Date:  2017-10-09       Impact factor: 2.744

4.  Correlation between factor (F)XIa, FIXa and tissue factor and trauma severity.

Authors:  Shannon M Prior; Mitchell J Cohen; Amanda S Conroy; Mary F Nelson; Lucy Z Kornblith; Benjamin M Howard; Saulius Butenas
Journal:  J Trauma Acute Care Surg       Date:  2017-06       Impact factor: 3.313

5.  Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.

Authors:  Rami A Al-Horani; Elnaz Parsaeian; Mariam Mohammad; Madhusoodanan Mottamal
Journal:  Chem Biol Drug Des       Date:  2022-04-11       Impact factor: 2.873

6.  Continuous thrombin generation in whole blood: New applications for assessing activators and inhibitors of coagulation.

Authors:  Shannon M Prior; Kenneth G Mann; Kalev Freeman; Saulius Butenas
Journal:  Anal Biochem       Date:  2018-05-07       Impact factor: 3.365

7.  Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.

Authors:  Elena N Lipets; Fazoil I Ataullakhanov
Journal:  Thromb J       Date:  2015-01-23

8.  Genetic variants of coagulation factor XI show association with ischemic stroke up to 70 years of age.

Authors:  Ellen Hanson; Staffan Nilsson; Katarina Jood; Bo Norrving; Gunnar Engström; Christian Blomstrand; Arne Lindgren; Olle Melander; Christina Jern
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

9.  Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients.

Authors:  Elena Lipets; Olga Vlasova; Evdokiya Urnova; Oleg Margolin; Anna Soloveva; Olga Ostapushchenko; John Andersen; Fazoil Ataullakhanov; Mikhail Panteleev
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

10.  Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke.

Authors:  Piotr Kusak; Danuta Czarnecka; Matthew Gissel; Krzysztof Plens; Saulius Butenas; Anetta Undas
Journal:  Arch Med Sci       Date:  2015-11-17       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.